APO Research
Talk to an analyst

APO RESEARCH · REPORT

Finished Dosage Form Antithrombin

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Finished Dosage Form Antithrombin Market Outlook and Growth Opportunities 2026

12 August 2026197 pages

Choose your research edition.

Industry ResearchFinished Dosage Form Antithrombin Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Finished Dosage Form Antithrombin Industry Growth and Trends Forecast to 203286 pages · $3,450 USDMarket StructureGlobal Finished Dosage Form Antithrombin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Finished Dosage Form Antithrombin Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Finished Dosage Form Antithrombin Market Analysis and Forecast 2026-2032176 pages · $4,950 USD

Market perspective

The global Finished Dosage Form Antithrombin market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Finished Dosage Form Antithrombin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Finished Dosage Form Antithrombin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Finished Dosage Form Antithrombin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Finished Dosage Form Antithrombin market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Finished Dosage Form Antithrombin market include Kedrion S.p.A., CSL Limited, Scripps Laboratories Inc., Lee Biosolutions, Grifols, LFB S.A./rEVO Biologics Inc. and Takeda, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Finished Dosage Form Antithrombin market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Finished Dosage Form Antithrombin and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Finished Dosage Form Antithrombin revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Finished Dosage Form Antithrombin market.

Finished Dosage Form Antithrombin Segment by Company

Kedrion S.p.A.

CSL Limited

Scripps Laboratories Inc.

Lee Biosolutions

Grifols

LFB S.A./rEVO Biologics Inc.

Takeda

Finished Dosage Form Antithrombin Segment by Type

Liquid

Lyophilized

Finished Dosage Form Antithrombin Segment by Application

Diagnostics

Therapeutics

Finished Dosage Form Antithrombin Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Finished Dosage Form Antithrombin status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Finished Dosage Form Antithrombin key companies, revenue, market share, and recent developments.

3. To split the Finished Dosage Form Antithrombin breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Finished Dosage Form Antithrombin market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Finished Dosage Form Antithrombin significant trends, drivers, influence factors in global and regions.

6. To analyze Finished Dosage Form Antithrombin competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Finished Dosage Form Antithrombin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Finished Dosage Form Antithrombin and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Finished Dosage Form Antithrombin.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Finished Dosage Form Antithrombin industry.

Chapter 3: Detailed analysis of Finished Dosage Form Antithrombin company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Finished Dosage Form Antithrombin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Finished Dosage Form Antithrombin in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Finished Dosage Form Antithrombin Industry Trends Table 2. Finished Dosage Form Antithrombin Industry Drivers Table 3. Finished Dosage Form Antithrombin Industry Opportunities and Challenges Table 4. Finished Dosage Form Antithrombin Industry Restraints Table 5. Global Finished Dosage Form Antithrombin Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Finished Dosage Form Antithrombin Revenue Share by Company (2021-2026) Table 7. Global Finished Dosage Form Antithrombin Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Finished Dosage Form Antithrombin Key Company Manufacturing Base & Headquarters Table 9. Global Finished Dosage Form Antithrombin Company, Product Type & Application Table 10. Global Finished Dosage Form Antithrombin Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Finished Dosage Form Antithrombin by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Liquid Table 15. Significant Companies of Lyophilized Table 16. Global Finished Dosage Form Antithrombin Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Finished Dosage Form Antithrombin Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Finished Dosage Form Antithrombin Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Finished Dosage Form Antithrombin Sales Value Share by Type (2021-2026) Table 20. Global Finished Dosage Form Antithrombin Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Diagnostics Table 22. Significant Companies of Therapeutics Table 23. Global Finished Dosage Form Antithrombin Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global Finished Dosage Form Antithrombin Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global Finished Dosage Form Antithrombin Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global Finished Dosage Form Antithrombin Sales Value Share by Application (2021-2026) Table 27. Global Finished Dosage Form Antithrombin Sales Value Share by Application (2027-2032) Table 28. Global Finished Dosage Form Antithrombin Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Finished Dosage Form Antithrombin Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global Finished Dosage Form Antithrombin Sales Value Share by Region (2021-2026) Table 31. Global Finished Dosage Form Antithrombin Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global Finished Dosage Form Antithrombin Sales Value Share by Region (2027-2032) Table 33. Global Finished Dosage Form Antithrombin Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Finished Dosage Form Antithrombin Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global Finished Dosage Form Antithrombin Sales Value Market Share by Country (2021-2026) Table 36. Global Finished Dosage Form Antithrombin Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global Finished Dosage Form Antithrombin Sales Value Market Share by Country (2027-2032) Table 38. Kedrion S.p.A. Company Information Table 39. Kedrion S.p.A. Business Overview Table 40. Kedrion S.p.A. Finished Dosage Form Antithrombin Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. Kedrion S.p.A. Finished Dosage Form Antithrombin Product Portfolio Table 42. Kedrion S.p.A. Recent Development Table 43. CSL Limited Company Information Table 44. CSL Limited Business Overview Table 45. CSL Limited Finished Dosage Form Antithrombin Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. CSL Limited Finished Dosage Form Antithrombin Product Portfolio Table 47. CSL Limited Recent Development Table 48. Scripps Laboratories Inc. Company Information Table 49. Scripps Laboratories Inc. Business Overview Table 50. Scripps Laboratories Inc. Finished Dosage Form Antithrombin Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Scripps Laboratories Inc. Finished Dosage Form Antithrombin Product Portfolio Table 52. Scripps Laboratories Inc. Recent Development Table 53. Lee Biosolutions Company Information Table 54. Lee Biosolutions Business Overview Table 55. Lee Biosolutions Finished Dosage Form Antithrombin Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Lee Biosolutions Finished Dosage Form Antithrombin Product Portfolio Table 57. Lee Biosolutions Recent Development Table 58. Grifols Company Information Table 59. Grifols Business Overview Table 60. Grifols Finished Dosage Form Antithrombin Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Grifols Finished Dosage Form Antithrombin Product Portfolio Table 62. Grifols Recent Development Table 63. LFB S.A./rEVO Biologics Inc. Company Information Table 64. LFB S.A./rEVO Biologics Inc. Business Overview Table 65. LFB S.A./rEVO Biologics Inc. Finished Dosage Form Antithrombin Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. LFB S.A./rEVO Biologics Inc. Finished Dosage Form Antithrombin Product Portfolio Table 67. LFB S.A./rEVO Biologics Inc. Recent Development Table 68. Takeda Company Information Table 69. Takeda Business Overview Table 70. Takeda Finished Dosage Form Antithrombin Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Takeda Finished Dosage Form Antithrombin Product Portfolio Table 72. Takeda Recent Development Table 73. Research Programs/Design for This Report Table 74. Authors List of This Report Table 75. Secondary Sources Table 76. Primary Sources List of Figures Figure 1. Finished Dosage Form Antithrombin Product Image Figure 2. Global Finished Dosage Form Antithrombin Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Finished Dosage Form Antithrombin Market Size (2021-2032) & (US$ Million) Figure 4. Global Finished Dosage Form Antithrombin Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Liquid Image Figure 8. Lyophilized Image Figure 9. Global Finished Dosage Form Antithrombin Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Finished Dosage Form Antithrombin Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Finished Dosage Form Antithrombin Sales Value Share by Type (2021-2032) Figure 12. Diagnostics Image Figure 13. Therapeutics Image Figure 14. Global Finished Dosage Form Antithrombin Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Finished Dosage Form Antithrombin Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Finished Dosage Form Antithrombin Sales Value Share by Application (2021-2032) Figure 17. Global Finished Dosage Form Antithrombin Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Finished Dosage Form Antithrombin Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America Finished Dosage Form Antithrombin Sales Value (2021-2032) & (US$ Million) Figure 20. North America Finished Dosage Form Antithrombin Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe Finished Dosage Form Antithrombin Sales Value (2021-2032) & (US$ Million) Figure 22. Europe Finished Dosage Form Antithrombin Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific Finished Dosage Form Antithrombin Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific Finished Dosage Form Antithrombin Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America Finished Dosage Form Antithrombin Sales Value (2021-2032) & (US$ Million) Figure 26. South America Finished Dosage Form Antithrombin Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa Finished Dosage Form Antithrombin Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa Finished Dosage Form Antithrombin Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • Liquid
  • Lyophilized
Applications
  • Diagnostics
  • Therapeutics
Companies covered
  • Kedrion S.p.A.
  • CSL Limited
  • Scripps Laboratories Inc.
  • Lee Biosolutions
  • Grifols
  • LFB S.A./rEVO Biologics Inc.
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Finished Dosage Form Antithrombin Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Finished Dosage Form Antithrombin Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Finished Dosage Form Antithrombin Market Dynamics
  1. 2.1 Finished Dosage Form Antithrombin Industry Trends
  2. 2.2 Finished Dosage Form Antithrombin Industry Drivers
  3. 2.3 Finished Dosage Form Antithrombin Industry Opportunities and Challenges
  4. 2.4 Finished Dosage Form Antithrombin Industry Restraints
3 Finished Dosage Form Antithrombin Market by Company
  1. 3.1 Global Finished Dosage Form Antithrombin Company Revenue Ranking in 2025
  2. 3.2 Global Finished Dosage Form Antithrombin Revenue by Company (2021-2026)
  3. 3.3 Global Finished Dosage Form Antithrombin Company Ranking (2024-2026)
  4. 3.4 Global Finished Dosage Form Antithrombin Company Manufacturing Base and Headquarters
  5. 3.5 Global Finished Dosage Form Antithrombin Company Product Type and Application
  6. 3.6 Global Finished Dosage Form Antithrombin Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Finished Dosage Form Antithrombin Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Finished Dosage Form Antithrombin Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Finished Dosage Form Antithrombin Market by Type
  1. 4.1 Finished Dosage Form Antithrombin Type Introduction
  2. 4.1.1 Liquid
  3. 4.1.2 Lyophilized
  4. 4.2 Global Finished Dosage Form Antithrombin Sales Value by Type
  5. 4.2.1 Global Finished Dosage Form Antithrombin Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Finished Dosage Form Antithrombin Sales Value by Type (2021-2032)
  7. 4.2.3 Global Finished Dosage Form Antithrombin Sales Value Share by Type (2021-2032)
5 Finished Dosage Form Antithrombin Market by Application
  1. 5.1 Finished Dosage Form Antithrombin Application Introduction
  2. 5.1.1 Diagnostics
  3. 5.1.2 Therapeutics
  4. 5.2 Global Finished Dosage Form Antithrombin Sales Value by Application
  5. 5.2.1 Global Finished Dosage Form Antithrombin Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Finished Dosage Form Antithrombin Sales Value by Application (2021-2032)
  7. 5.2.3 Global Finished Dosage Form Antithrombin Sales Value Share by Application (2021-2032)
6 Finished Dosage Form Antithrombin Regional Value Analysis
  1. 6.1 Global Finished Dosage Form Antithrombin Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Finished Dosage Form Antithrombin Sales Value by Region (2021-2032)
  3. 6.2.1 Global Finished Dosage Form Antithrombin Sales Value by Region: 2021-2026
  4. 6.2.2 Global Finished Dosage Form Antithrombin Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Finished Dosage Form Antithrombin Sales Value (2021-2032)
  7. 6.3.2 North America Finished Dosage Form Antithrombin Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Finished Dosage Form Antithrombin Sales Value (2021-2032)
  10. 6.4.2 Europe Finished Dosage Form Antithrombin Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Finished Dosage Form Antithrombin Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Finished Dosage Form Antithrombin Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Finished Dosage Form Antithrombin Sales Value (2021-2032)
  16. 6.6.2 South America Finished Dosage Form Antithrombin Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Finished Dosage Form Antithrombin Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Finished Dosage Form Antithrombin Sales Value Share by Country, 2025 VS 2032
7 Finished Dosage Form Antithrombin Country-level Value Analysis
  1. 7.1 Global Finished Dosage Form Antithrombin Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Finished Dosage Form Antithrombin Sales Value by Country (2021-2032)
  3. 7.2.1 Global Finished Dosage Form Antithrombin Sales Value by Country (2021-2026)
  4. 7.2.2 Global Finished Dosage Form Antithrombin Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Finished Dosage Form Antithrombin Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Finished Dosage Form Antithrombin Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Finished Dosage Form Antithrombin Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Kedrion S.p.A.
  2. 8.1.1 Kedrion S.p.A. Company Information
  3. 8.1.2 Kedrion S.p.A. Business Overview
  4. 8.1.3 Kedrion S.p.A. Finished Dosage Form Antithrombin Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Kedrion S.p.A. Finished Dosage Form Antithrombin Product Portfolio
  6. 8.1.5 Kedrion S.p.A. Recent Developments
  7. 8.2 CSL Limited
  8. 8.2.1 CSL Limited Company Information
  9. 8.2.2 CSL Limited Business Overview
  10. 8.2.3 CSL Limited Finished Dosage Form Antithrombin Revenue and Gross Margin (2021-2026)
  11. 8.2.4 CSL Limited Finished Dosage Form Antithrombin Product Portfolio
  12. 8.2.5 CSL Limited Recent Developments
  13. 8.3 Scripps Laboratories Inc.
  14. 8.3.1 Scripps Laboratories Inc. Company Information
  15. 8.3.2 Scripps Laboratories Inc. Business Overview
  16. 8.3.3 Scripps Laboratories Inc. Finished Dosage Form Antithrombin Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Scripps Laboratories Inc. Finished Dosage Form Antithrombin Product Portfolio
  18. 8.3.5 Scripps Laboratories Inc. Recent Developments
  19. 8.4 Lee Biosolutions
  20. 8.4.1 Lee Biosolutions Company Information
  21. 8.4.2 Lee Biosolutions Business Overview
  22. 8.4.3 Lee Biosolutions Finished Dosage Form Antithrombin Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Lee Biosolutions Finished Dosage Form Antithrombin Product Portfolio
  24. 8.4.5 Lee Biosolutions Recent Developments
  25. 8.5 Grifols
  26. 8.5.1 Grifols Company Information
  27. 8.5.2 Grifols Business Overview
  28. 8.5.3 Grifols Finished Dosage Form Antithrombin Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Grifols Finished Dosage Form Antithrombin Product Portfolio
  30. 8.5.5 Grifols Recent Developments
  31. 8.6 LFB S.A./rEVO Biologics Inc.
  32. 8.6.1 LFB S.A./rEVO Biologics Inc. Company Information
  33. 8.6.2 LFB S.A./rEVO Biologics Inc. Business Overview
  34. 8.6.3 LFB S.A./rEVO Biologics Inc. Finished Dosage Form Antithrombin Revenue and Gross Margin (2021-2026)
  35. 8.6.4 LFB S.A./rEVO Biologics Inc. Finished Dosage Form Antithrombin Product Portfolio
  36. 8.6.5 LFB S.A./rEVO Biologics Inc. Recent Developments
  37. 8.7 Takeda
  38. 8.7.1 Takeda Company Information
  39. 8.7.2 Takeda Business Overview
  40. 8.7.3 Takeda Finished Dosage Form Antithrombin Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Takeda Finished Dosage Form Antithrombin Product Portfolio
  42. 8.7.5 Takeda Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst